Gadobutrol

Gadobutrol
Systematic (IUPAC) name
	gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Clinical data
AHFS/Drugs.com	International Drug Names
Licence data	US FDA:link
Pregnancy; category	US: C (Risk not ruled out); ;
Legal status	UK: POM (Prescription only); US: ℞-only;
Routes of; administration	IV
Identifiers
CAS Number	138071-82-6
ATC code	V08CA09 (WHO)
PubChem	CID: 72057
DrugBank	DB06703
UNII	1BJ477IO2L
KEGG	D07420
ChEBI	CHEBI:68841
ChEMBL	CHEMBL1628503
Chemical data
Formula	C18H31GdN4O9
Molecular mass	604.710 g/mol
	SMILES C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Ga+3] ;
(what is this?) (verify)

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

It received marketing approval in Canada^[1] and in the United States.^[2]^[3]^[4]

As of 2007, it was the only GBCA approved at 1.0 molar concentrations.^[5]

Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.^[6]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.